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     The effect of metyrapone on the augmented adrenal 17-hydroxycorticosteroid (17-
OHCS) secretion induced by the administration of adrenocorticotrophin (ACTH) was 
investigated in dogs. 
     A single intravenous injection of ACTH (1 i.u./kg) resulted in the markedly 
increased secretion of adrenal 17-OHCS; the peak was attained within 60 minutes, and 
sustained over 3 hours. At the time when the secretion rate caused by ACTH was at a 
maximum, an intravenous injection of metyrapone (40 mg or 60 mg/kg) produced a rapid 
and marked decrease in adrenal 17-OHCS secretion. This diminution occurred within 
15 minutes and the effect was reversible.
                   INTRODUCTION 
     There are several compounds which can inhibit the synthesis of certain adrenocor-
tical hormones. Among them, the effect of amphenone B has been provided by the con-
vincing data of ROSENFELD & BASCOM81, indicating that amphenone B suppress 11p-, 
17a- and 21-hydroxylation and the oxidation of a A5-3p-hydroxyl groups to A4-3-ketone in 
the adrenal cortex. A similar effect was found in the biological activity of methylene-
dianilinell-13n and of perthane10). Metyrapone also is an amphenone analogue 2) but 
unlike amphenone and methylenedianiline it has been shown by LIDDLE, ISLAND, 
LANCE & HARRIS') to inhibit selectively the enzymatic system responsible for 11(3-
hydroxylation of steroids.
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      Therefore, in the present study it seemed desirable to test how the 17-hydroxycortico-
steroid secretory response of the adrenal gland in response to the administration of adreno-
corticotrophin is influenced by metyrapone. This was demonstrated by measuring quanti-
tatively the level of 17-hydroxycorticosteroids in adrenal venous blood. 
               MATERIALS AND METHODS 
      Mongrel male adult dogs, weighing 7.9 to 15.3 kg, were used in these experi-
ments. On the previous day of observation, each animal was anesthetized with 25 mg/ 
kg of sodium pentobarbital given into the left saphenous vein. Immediately after ane-
sthetization, the left lumboadrenal vein was approached through a longitudinal incision in 
the left lumbar area, in a fashion similar to the method of SATAKE, SUGAWARA & 
WATANABE9), and then accessory branches of the vessel were ligated and sectioned. 
A silk thread was passed loosely around the vein which connects the adrenal gland to 
the inferior vena cava. After systemic administration of heparin, a small glass cannula 
fitted with a rubber tube was inserted into the exposed lumboadrenal vein. By pulling 
at a ligature, the entire blood flow through the adrenal gland is obtainable. When a 
ligature is released, blood can flow from the adrenal gland to the inferior vena cava 
during periods when it is not being collected. After refilling a cannula with a heparin-
saline solution, the animal was allowed to recover for approximately 18 hours prior to the 
collection of adrenal blood samples. 
      On the day of observation, the animal was again reanesthetized with sodium pento-
barbital (25 mg/kg, injected intravenously). Approximately 2 to 3 hours later, the coll-
ection of control samples of adrenal venous blood was begun. A single injection of 1 i . u . 
adrenocorticotrophin (ACTH)/kg body weight was made into the left saphenous vein 
for 15 seconds. Timed adrenal venous blood was sampled 15, 30 and 60 minutes after 
the injection of ACTH. Seventy-five minutes after the injection of ACTH, either me-
tyrapone ditartrate (Ciba Ltd) (40 mg or 60 mg/kg) or isotonic saline only was injected 
into the left saphenous vein in a single dose of 2 ml for 30 seconds. Further samples 
of adrenal venous blood were collected 90, 120 and 180 minutes after the injection of 
ACTH. 
     The blood was chilled immediately and centrifuged under refrigeration. One milli-
liter of plasma was analysed for 17-hydroxycorticosteroids (17-OHCS) by the method of 
PORTER & SILBER". 
     Finally, the secretion rate of 17-OHCS by one adrenal gland (pg/kg/min) was 
calculated by multiplying the concentration of 17-OHCS in adrenal venous plasma(,ag/ml) 
by the adrenal venous plasma flow (ml/kg/min).
                     RESULTS 
       The secretory response of adrenal 17-hydroxycorticosteroids to the admini-
       stration of adrenocorticotrophin 
     Representive results are shown in Fig. 1. The basal rates of 17-hydroxycortico-
steroids (17-OHCS), established by samples taken 20 and 10 minutes prior to the
Fig. 1. Effect of corticotrophin (ACTH) stimulation on adrenal 17-hydroxycorticosteroid 
        (17-OHCS) secretion in dogs. ACTH was given intravenously in a dose of 1 i.u. 
       /kg. Additionally, isotonic saline was injected intravenously in 2 ml 75 minutes
        after the injection of ACTH. Each column represents the mean±SE in adrenal 
        17-OHCS secretion of five dogs at various times after the injection of ACTH.
injection of adrenocorticotrophin (ACTH), were extremely low. Following an intravenous 
injection of ACTH in a dose of 1 i.u./kg, there was the markedly increased secretion of 
adrenal17-OHCS. The maximum rate occurred within 60 minutes. Seventy-five minutes 
after the injection of ACTH, isotonic saline was injected via the intravenous route, 
ACTH-induced increase in the secretion was not influenced by this treatment and lasted 
over the 3-hour period of observation. These results show that the stimulating effect of 
ACTH on adrenal secretion of 17-OHCS was not affected by treatment with isotonic 
saline. 
       Effects of metyrapone on the increased secretion of adrenal 17-hydroxy-
       corticosteroids produced by the administration of adrenocorticotrophin 
      As can be seen in Fig. 2, an intravenous administration of metyrapone, performed 
at 75 minutes after the injection of ACTH effected a prompt and marked decrease
Fig. 2. Inhibitory effect of metyrapone on the increased secretion of adrenal 17-hydroxy-
       corticosteroids caused by corticotrophin (ACTH). Metyrapone was injected 
       into the left saphenous vein 75 min after the injection of ACTH: (metyrapone, 
       40 mg or 60 mg/kg; ACTH, 1 i . u. /kg) . Each bar shows the mean±SE of 5 
       dogs in adrenal 17-OHCS secretion at various times after the ACTH injection. 
       ® . ACTH 1 i. u./kg, metyrapone 40 mg/kg; . ACTH 1 i.u./kg, 
       metyrapone 60 mg/kg.
in adrenal 17-OHCS secretion. When 40 mg/kg of metyrapone was given (Fig. 2), a 
remarkable inhibition of secretion was observed 15 minutes later, but it tended to re-
cover within approximately 2 hours. The secretory response to ACTH at 15 minutes 
after the injection of metyrapone showed a reduction of 39%, as compared with that 
of controls. With higher doses up to 60 mg/kg (Fig. 2) , there was much lowered se-
cretion of adrenal 17-OHCS, showing an inhibition of 58% at 15 minutes after the 
administration. The inhibitory activity of this dose was more enhanced and prolonged 
than that with lower doses. The effect lasted over 2 hours. 
                    DISCUSSION 
     In the present results, a marked increase in adrenal 17-OHCS secretion in response 
to exogenous ACTH could largerly be inhibited by treatment with metyrapone. An 
inhibition in the secretion occurred soon after the treatment, and the effect was reversible. 
     The present findings agree with the early work of CHART, SHEPPARD, ALLEN, 
BENCZE & GAUNT'), in which it was shown that in the dog the administration of 10 
to 30 mg of metyrapone ditartrate produced a reduction in adrenal venous corticoids 
from 25% to nearly 100% below pretreatment control values. In 4 endocrinologically 
normal individuals, LIDDLE, ISLAND, LANCE & HARRISO have shown that intrave-
nous treatment with metyrapone resulted in a rapid and marked fall in the level of hydro-
cortisone in adrenal venous blood. Such a decrease in the secretion may usually be el-
icited by either an impairment of release of hormone, a decreased hormone synthesis, or 
a combination of these possible alterations. For this favor, evidence for the enzymatic 
system in the adrenal cortex as the focus of inhibition by metyrapone has been obtained 
from experiments in vivo and in vitro. In vitro experiments performed by CALLOW, 
CALLOW & EMMENSI), the activity of 11j3-hydroxylase obtained from bovine adrenal 
tissue was almost totally inhibited by an addition of a 1.5x10-5 molar solution of 
metyrapone, and was 50% inhibited by a 2.5X 10-6 molar solution. In contrast, 21-
hydroxylase was not inhibited by a 1 x 10-3 molar. CHART et al.21 have demonstrated 
in their in vitro experiments that metyrapone suppressed the release of corticoids when 
applied with ACTH to canine adrenal slices. These findings suggest a possible 
inhibition of 11(3-hydroxylation reactions in the adrenal tissue as the site of action of 
metyrapone. Furthermore, LIDDLE et al.6) have investigated systemically for the me-
chanism of action of metyrapone. They observed that in subjects having normal adreno-
cortical function the prolonged oral or intravenous administration of metyrapone caused 
a marked fall in the level of plasma 17-OHCS, urinary 17-OHCS and 17-ketosteroids. 
From these results they pointed out that metyrapone might act as a specific inhibitor of 
11(3-hydroxylation of steroids by the adrenal cortex. This hypothesis was also confirmed 
by JENKINS, MEAKIN & NELSONS) in the dog, GOLD, BIGLER, NEWMAN, ANGERS 
& DIRAIMONDO3) and JENKINS, MEAKIN & NELSON 4) in man. 
     From the results mentioned above it seems that the inhibitory effect of metyrapone 
observed in the present study is not due to an impairment of release of 17-OHCS 
by the adrenal, but to a block of biosynthesis of these hormones. Although 11-deoxy-
cortisol and cortisol are the main 17-OHCS secreted by the adrenal, considering from 
pathways of biosynthesis of 17-OHCS the secretion of 11-deoxycortisol caused by ACTH 
is probably not inhibited by metyrapone. The finding of this study showed that the 
adrenal 17-OHCS secretory activity resulting from the administration of 1 i . u . ACTH/kg 
was inhibited approximately 39 to 58% by doses of 40 mg to 60 mg/kg of metyrapone. 
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